Kaigene Inc. has entered into a licensing agreement with Taisho Pharmaceutical Co. Ltd. for the exclusive development and commercialization of Kaigene’s next-generation human neonatal Fc receptor (FcRn) inhibitor, KG-006, in Japan.
Mirador Therapeutics Inc. has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a antibody with potential to treat ANCA-associated vasculitis.
Uniquest Pty Ltd., the commercialization company of the University of Queensland, has entered into an exclusive license agreement with the Ellison Medical Institute (EMI) to develop and commercialize the University of Queensland’s QED-203 for metastatic castration-resistant prostate cancer.
Flobiotech GmbH has signed an agreement with UCLA Health to advance a novel class of therapeutics targeting biologically validated protective pathways in neurodegeneration.
Boehringer Ingelheim Pharma GmbH & Co. KG and Immunitas Therapeutics Inc. have signed a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases.
Astrazeneca plc has exercised an option under its collaboration with Pinetree Therapeutics Inc. to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise triggers a $25 million payment to Pinetree.
Kazia Therapeutics Ltd. has licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The company acquired global rights to the SETDB1 platform, including the lead candidate MSETC, in exchange for an up-front payment and a tiered revenue-sharing structure aligned with development progress.
Haisco Pharmaceutical Group Co. Ltd. has entered into an exclusive licensing agreement with Abbvie Inc., granting Abbvie the exclusive rights to develop, manufacture and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong and Macau.
Gilead Sciences Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera Therapeutics Inc. under the parties’ strategic collaboration agreement.
RSS
